TFG News

Topics

Medication Prices Often Lower Without Insurance

The cost of prescription drugs — in particular, generics — is increasingly lower when patients purchase the medications directly from online suppliers and leave their insurance cards out of the equation, according to a collaborative effort by the New York Times and ProPublica. The story, linked below, takes a closer look at the whys and implications.

https://www.propublica.org/article/when-buying-prescription-drugs-some-pay-more-with-insurance-than-without-it

 

Medication Prices Often Lower Without Insurance

The cost of prescription drugs — in particular, generics — is increasingly lower when patients purchase the medications directly from online suppliers and leave their insurance cards out of the equation, according to a collaborative effort by the New York Times and ProPublica. The story, linked below, takes a closer look at the whys and implications.

https://www.propublica.org/article/when-buying-prescription-drugs-some-pay-more-with-insurance-than-without-it

 

Response: Call them what you want, but it is all just brand or generics.

by Dr. Franco Mueller
Partner/Medical Director, TFG Partners

We remain a bit skeptical of the studies mentioned in our previous post from KHN. Please look at the study dates, the data is from  between 2007 and 2013. Many Pharma companies have boosted the price in the last two years and we are just seeing costs continue to skyrocket. There are more problems facing employers then just orphan drugs in the industry pipeline. The issues go much deeper into the pharmaceutical industry and orphan drugs are just one part of the horizon.  more

Study Says Concerns About Orphan Drug Spending Are Unjustified

 | September 7

Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs.

“We wanted to focus on the true impact of orphan drugs,” said Victoria Divino, a senior consultant at IMS Health and an author of the study. Researchers at IMS Health and drug maker Celgene analyzed U.S. pharmaceutical spending from 2007 to 2013 on more than 300 drugs that had orphan approval under the 1983 Orphan Drug Act. more

Study Says Concerns About Orphan Drug Spending Are Unjustified

 | September 7

Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs.

“We wanted to focus on the true impact of orphan drugs,” said Victoria Divino, a senior consultant at IMS Health and an author of the study. Researchers at IMS Health and drug maker Celgene analyzed U.S. pharmaceutical spending from 2007 to 2013 on more than 300 drugs that had orphan approval under the 1983 Orphan Drug Act. more

Smaller Companies Move to Self-Funding

Many expected that the federal health law would push these employers in this direction. An analysis by the Employee Benefit Research Institute finds evidence that these predictions are coming to fruition.

Instead of buying a health insurance policy to cover their workers, a growing number of small and mid-sized companies are opting to pay their employees’ medical claims directly, a potentially riskier practice financially called self-insuring, a recent study found. more

Smaller Companies Move to Self-Funding

Many expected that the federal health law would push these employers in this direction. An analysis by the Employee Benefit Research Institute finds evidence that these predictions are coming to fruition.

Instead of buying a health insurance policy to cover their workers, a growing number of small and mid-sized companies are opting to pay their employees’ medical claims directly, a potentially riskier practice financially called self-insuring, a recent study found. more

A New Bariatric Approach – A Valve in Your Stomach


According to an article posted on CNBC.com today, AspireBariatrics has received FDA approval for it’s AspireAssit device. The AspireAssit device allows the patient to discard 30% of the calories they have consumed from a recent meal directly into  the toilet.  With this interesting approach to surgical weight loss, participants in the clinical trial lost an average of 12.1 percent of their body fat in a year.

We will be interested to see how insurers and employers approach paying for this device as some professionals consider the device an “enabling device” as opposed to something helpful or behavior modifying,

Read Robert Ferris’ article “The FDA-approved a weightloss device that sucks frood from your stomach” on CNBC.com

The Wall Street Journal — Insiders Guide to Pittsburgh, Pa. – WSJ.com

Pittsburgh is the home to a booming downtown culture that is continuing to undergo a transformation from its days as the worlds steel super-producer. TFG Partners is proud to be located int the heart of the “Golden Triangle” and be part of this renaissance. To show our ” Burg Pride” we extend to you this great article and guide from the Wall Street Journal:

Via The Wall Street Journal:

THIS IS ONE RUST BELT town that’s gotten a polish. After decades of losing jobs and residents, Pittsburgh has become a standard-bearer for urban revitalization.

Joining its distinctive, bridge-studded skyline are ambitious buildings like the modernist Tower at PNC Plaza, expected to open in 2015 as the world’s greenest skyscraper, and the Gardens at Market Square, a $90 million high-rise. Downtown is undergoing a gold rush, with old factories and closed department stores being converted rapid-fire into apartments and spaces for new businesses.

Read more on the WSJ — Journal Concierge: Insiders Guide to Pittsburgh, Pa. – WSJ.com.

Forbes: To Bring Healthcare Prices Down, Consumers Must Demand Price Transparency

Healthcare price transparency is on the leading edge to finding the solution. This article by Giovanni Colella ties back in with last month’s Time Magazine article and continues to highlight

Credit: PinkBlue / FreeDigitalPhotos.net

Credit: PinkBlue / FreeDigitalPhotos.net

the nessesity of making pricing of procedures public and transparent.  At TFG Partners, we receive pushback on requests from administrators for necessary pricing information. Along with other industry leaders, TFG Partners will continue to work on the forefront to gain the upper hand for our clients.

To Bring Healthcare Prices Down, Consumers Must Demand Price Transparency